Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
-
Narrated by:
-
By:
About this listen
Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD.
Related Content:
- Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
activate_mytile_page_redirect_t1
What listeners say about Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.